We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA faces new pressure to accelerate its review of the controversial Plan B contraceptive after a leading congressional critic released internal agency documents that call into question the FDA’s rationale for delaying a decision on the product.